Qiming Venture Partners
Qiming joins Series B for Chinese AI diagnosis player
Shukun, a Chinese start-up that develops artificial intelligence (AI) technology used in the medical imaging diagnosis, has raised RMB200 million in the third tranche of Series B round.
RA Capital leads round for China's Connect Biopharma
Connect Biopharma, a drug developer based in China and the US, has raised $115 million in Series C funding led by RA Capital Management.
China’s VC-backed CanSino raises $748m in Star Market IPO
Chinese vaccine developer CanSino Biologics, which counts Lily Asia Ventures (LAV) and Qiming Venture Partners among its investors, has raised RMB5.2 billion ($748 million) in an IPO on Shanghai’s Star Market.
Sequoia leads Series B for Chinese intelligent sales player
Tungee, a Chinese sales-focused software-as-a-service (SaaS) platform, has raised RMB120 million ($17 million) in a Series B round led by Sequoia Capital China. Qiming Venture Partners also took part.
DCP, Qiming support China medical devices fund
Ascendum Capital Partners, a healthcare investment firm established by DCP Capital, Qiming Venture Partners and Chinese medical devices manufacturer Venus Medtech, is looking to raise $200 million for its debut fund.
China cancer test kit provider gets $30m Series E
New Horizon Health, a China-based manufacturer of cancer testing kits for use at home, has raised $30 million in a Series E round of funding led by Rock Springs Capital.
China IPOs: Star attraction
Having previously focused on offshore IPOs, China managers with US dollar funds are now considering the Star Market. But going onshore means more regulation as well as high valuations
China data storage provider XSKY raises $45m
China-based data storage software services provider XSKY has raised a RMB320 million ($45 million) Series D led by China's State Owned Venture Capital Fund.
China's Gan & Lee Pharmaceuticals gains after A-share debut
Chinese insulin manufacturer Gan & Lee Pharmaceuticals, which counts Qiming Venture Partners and Goldman Sachs among its investors, raised RMB2.5 billion ($354 million) through an A-share IPO.
VC-backed SinocellTech enjoys strong Star Market debut
Chinese drug developer SinocellTech nearly trebled in value on its first day of trading on China's Science and Technology Innovation Board (Star Market) following a RMB1.28 billion ($181 million) IPO.
China's Miaoshou Doctor raises $85m
Miaoshou Doctor, a Chinese online healthcare services platform, has raised RMB600 million ($85 million) in the first tranche of Series D funding round backed by the likes of Qiming Venture Partners, Sequoia Capital China, Ince Capital Partners, CITIC...
Chinese AI chip maker Biren raises $155m Series A
Biren Technology, a nine-month-old Chinese smart chip design company, has raised RMB1.1 billion ($155 million) in Series A funding led by Qiming Venture Partners, IDG Capital and Walden International.
GGV leads round for Chinese community group buying business
Shihuituan, a China-based community group buying platform also known as Nice Tuan, has raised $81.4 million in an extended Series C round led by GGV Capital.
Profile: Qiming Venture Partners' Duane Kuang
Having spent years as an IT advocate in a world obsessed with consumer internet start-ups, Duane Kuang of China-focused Qiming Venture Partners is seeing the tables gradually turn
Qiming leads round for Chinese display chip provider
Yunyinggu, a Chinese manufacturer of integrated circuits used in flat screen displays, has raised RMB200 million ($28 million) in Series C funding across two tranches.
Fund focus: Qiming’s triumph of quick thinking
Having overcome coronavirus disruption to close its seventh fund at $1.1 billion, Qiming Venture Partners is ready to go bigger on China healthcare
Qiming defies coronavirus to close seventh China fund at $1.1b
Qiming Venture Partners has closed its seventh US dollar-denominated China fund at $1.1 billion following an approximately two-month process that involved a last-minute relocation of on-site due diligence from Shanghai to San Francisco.
Temasek leads $70m Series C for China's Abbisko Therapeutics
Temasek Holdings has led a $70 million Series C round for Chinese drug developer Abbisko Therapeutics.
First responders: China VCs on a healthcare crisis
The coronavirus outbreak has thrust Chinese healthcare services into the spotlight, prompting investors to identify to sub-segments with potential for significant growth
Joy Capital leads $88m round for China's Shihuituan
Joy Capital has announced its participation - as the lead investor - in an $88.3m funding round for Chinese community group buying platform Shihuituan, which is also known as Nice Tuan.
China's Qiming names Grace Lee as COO
Grace Lee (pictured), has been appointed COO at Qiming Venture Partners, in addition to her existing roles as a partner and CFO – one of several people moves within the Chinese venture capital firm.
Lightspeed, Bosch lead $173m round for China's Hesai
Chinese smart sensor maker Hesai Technology has raised a $173 million Series C round led by Germany’s Bosch Group and existing investor Lightspeed China Partners.
China's KeChow Pharma gets $45m Series C
Shanghai Kechow Pharma, a Chinese small molecule targeted drug developer, has raised a $45 million Series C round led by Decheng Capital.
VCs set for exit as Alibaba buys IDsManager
Alibaba Cloud, the cloud computing unit of Alibaba Group, has agreed to acquire IDsManager, a Chinese cloud-based ID management platform backed by Qiming Venture Partners and Fortune Capital.